Perifosine: Update on a novel Akt inhibitor

@article{Gills2009PerifosineUO,
  title={Perifosine: Update on a novel Akt inhibitor},
  author={Joell J. Gills and Phillip A. Dennis},
  journal={Current Oncology Reports},
  year={2009},
  volume={11},
  pages={102-110}
}
The PI3K/Akt/mTOR pathway is aberrantly active in most human cancers and contributes to cell growth, proliferation, and survival. Akt is a nodal regulator of cellular survival pathways and an attractive target in cancer therapy. Many inhibitors of Akt are being developed. Perifosine is an oral Akt inhibitor currently being tested in phase 2 clinical trials. Unlike most kinase inhibitors, which target the adenosine triphosphate-binding region, perifosine targets the pleckstrin homology domain of… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 103 CITATIONS, ESTIMATED 42% COVERAGE

PTEN–GSK3β–MOB1 axis controls neurite outgrowth in vitro and in vivo

  • Cellular and Molecular Life Sciences
  • 2018
VIEW 2 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

AEG-1 Is a Target of Perifosine and Is Over-Expressed in Gastric Dysplasia and Cancers

  • Digestive Diseases and Sciences
  • 2013
VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Primordial follicle activation as new treatment for primary ovarian insufficiency

Hye Nam Lee, Eun Mi Chang
  • Clinical and experimental reproductive medicine
  • 2019
VIEW 1 EXCERPT
CITES BACKGROUND

FILTER CITATIONS BY YEAR

2009
2019

CITATION STATISTICS

  • 8 Highly Influenced Citations